Check out this article! I’ve been asking where the “PrEP is 99% effective” claim is really coming from, and it seems that there has been, at long last, a study that claims to prove this figure is true. Here it is:
New study confirms HIV preventive drug PrEP to be 99 per cent effective
There is only one problem. The “new study,” referred to in the headline, is the so-called British “Impact Trial,” and the “efficacy of PrEP” that they calculated pursuant to the study was not 99%. It was 86%.
Now, you might still be impressed with the 86% figure, as it represents a nontrivial increase from, say, the 43% estimate from the iPrex trial. Never mind that the analysis of iPrex managed to extrapolate the 43% out to the 99% that they assumed would occur given perfect adherence. Never mind that these statistical shenanigans are being used constantly. There are some oddities about the Impact Trial in both design and analysis, and I hope to have an in-depth examination of this study by the weekend. I might throw in iPrex too for fun and comparison. One thing I would like to make very clear is that what the Impact Trial did was not an actual “clinical trial” in the scientific sense; it was more of a retrospective study, whose results are typically considered inferior to those of controlled trials. However, as we know, true controlled trials are considered “unethical” in AIDS research, so the information we are going to get is necessarily less reliable than it could be.
Another thing that perplexes not only me but other mathematicians is that their definition of “efficacy” is unclear. Over what period of time? How many encounters? At even 86%, you would think that over time, this would translate to a lot of “seroconversions.” As I’ve said before, PrEP ought to be darn near perfect to justify such aggressive marketing that comes dangerously close to coercion. Here’s a thought experiment. Would you feel okay having an elective surgical procedure that had a 14% chance of failing?
But the problem isn’t really the number that they come up with; the problem is that the headline linked above is a blatant lie. Here’s the opening:
A new study has found a preventive HIV drug to be highly effective.
The study, called “the PrEP (Pre-Exposure Prophylaxes) Impact Trial”, was conducted by the UK Health Security Agency (UKHSA), with Chelsea and Westminster Hospital NHS Foundation Trust.
[…]
According to the study, PrEP, a drug that stops HIV from infecting the body has now been proven to be highly effective in the “real world” as a preventative treatment.
It is unclear where they got the 99% cited in the headline. It takes more than half the article for the “truth” to come out.
The study found that the use of PrEP reduced the chances of getting infected with HIV by around 86 per cent when used in everyday life, taking into consideration the account of inconsistent or incorrect use. On the other hand, clinical trials suggested that the medication is 99 per cent effective.
Ah, there it is. “Clinical trials suggested” that the medication is 99 per cent effective. Give me one single clinical trial of PrEP that DEMONSTRATES—not infers, demonstrates—such a high efficacy rate for PrEP. I’ve been waiting for a while.
This is the game being played. It has always been the game. If you’re Gen X (like I am) or older you probably remember AZT being touted as a miracle drug in the mainstream media. You probably also remember the protease inhibitors being lauded as having ended AIDS, despite causing liver failure, lipodystrophy, and cardiovascular disease in many patients. So what is going to happen with PrEP? Here’s a hint: Truvada is the drug being used for PrEP. Truvada has failed already. And the game gets a whole lot more sinister when “AIDS journalists” and “science journalists” publish articles like this that use blatantly deceptive language in the title. How many more lies are we being told? And why does no one seem to even care?
Moral of the story: Headlines are click bait, but when people don’t even bother to click, and sometimes even when they do, they are very easy to deceive.
To support my work on Substack, please purchase my book for yourself or for a friend, and leave a review on Amazon. You can learn about efforts to ban my book here. You can also buy my new book Almost Cancelled. You can also upgrade to paid at any time.
If you’re a new reader and would like some background as to my views on HIV AIDS, including the “existence” question, please refer to this post and the links contained therein.
The Padian et al study showed a lack of seroconversions despite 282 "couple years" of follow up. The less rigorous retrospective arm of their trial estimated 1000 sexual contacts needed to transmit HIV from male to female, and 9000 to transmit from female to male. This makes it nearly impossible to believe a research study claiming to reduce this significantly using PreP - or anything else. You would need hundreds of participants and to follow them for at least 5 years (Rebecca you are the stats whiz so maybe you can correct my rough estimates). There are so many biases in pharmaceutical research that every drug study deserves careful review.
For example, studies that have no positive result or even worse, show "negative efficacy", do not get published and are instead buried in company vaults that are nearly inaccessible even with a Freedom of Information Act requests. Cochrane researchers Tom Jefferson and Carl Heneghan detailed their efforts to find the unpublished trials of Tamiflu and Relenza, and after many years they finally found that the drug companies' own studies showed that they caused more harm than good. Here is a quote about their efforts from one of their Substack posts:
The Story of Influenza Antivirals: Part 14: Moving beyond the confusion
TOM JEFFERSON AND CARL HENEGHAN
MAY 15, 2023
"As you may recall, we started with the idea of updating our adult Cochrane review (on Tamiflu and Relenza) in 2009. We swiftly learnt that no one outside manufacturer or regulator had seen the complete dataset of trials and that the published trials had been ghostwritten. ..."
"Our requests for data had met with confidentiality agreements and secrecy clauses. The key claims made by manufacturers, especially of Tamiflu/oseltamivir, was that it had effects on complications reducing respiratory tract complications, antibiotic use, and hospitalization in both healthy and "at-risk" adults. But no such effect was visible in published trials.
After 18 months after the start of our search for the evidence, we still could not answer several basic questions:
How many trials were there?
Who is responsible for each trial?
Why were large phase III trials (e.g. M76001, NAIA 3002) not published?
Who was responsible for the decision not to publish studies in which humans were randomised?
What were the harms and benefits of NIs?
Why were trials published ten years after their completion?"
They persisted for a few more years, and went through thousands of documents finally released through FOIA requests, and found that the adverse effects were worse than the benefits.
https://trusttheevidence.substack.com/p/the-story-of-influenza-antivirals-6ce
If only 1% of people who test positive for HIV ever get "AIDS" anyway, then ANY "prophylactic" preparation, even daily orange juice, will be 99% effective, according to statistics. And medical "efficacy" is always based on statistics, never on actual experiments to test hypotheses.